Related Experiment Video
Updated: Jul 3, 2026
08:50
Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
Cardiovascular dysfunction in patients with end-stage liver disease
Merceds Susan Mandell1, Mei-Yung Tsou
1Department of Anesthesiology, University of Colorado Health Sciences Center, Aurora, Colorado, USA.
Journal of the Chinese Medical Association : JCMA
|July 26, 2008
Summary
Patients with advanced liver disease often have undiagnosed cardiac issues, termed cirrhotic cardiomyopathy. This condition affects systolic and diastolic function, increasing heart failure risk, especially during stress like liver transplantation.
Area of Science:
- Cardiology
- Hepatology
- Internal Medicine
Background:
- Physicians previously assumed normal cardiac function in liver disease patients based on resting ejection fraction.
- Advanced liver disease is associated with significant cardiovascular complications.
- Cirrhotic cardiomyopathy is a recognized condition in patients with liver disease.
Purpose of the Study:
- To explore the pathophysiology of cardiovascular changes in end-stage liver disease.
- To highlight the cardiac risks associated with liver disease.
- To discuss the clinical implications of cirrhotic cardiomyopathy.
Main Methods:
- Review of existing literature on cardiac function in liver disease.
- Analysis of echocardiographic findings in patients with advanced liver disease.
- Discussion of physiological stress tests and their impact on cardiac performance.
Main Results:
- Patients with liver disease exhibit subtle systolic and diastolic dysfunction.
- Cardiac abnormalities become apparent under physiological stress, such as during liver transplantation.
- Defects in electromechanical coupling contribute to clinical consequences.
Conclusions:
- Cirrhotic cardiomyopathy, characterized by cardiac dysfunction, is prevalent in all patients with liver disease.
- Understanding these cardiac changes is crucial for managing patients with end-stage liver disease.
- Early recognition and management of cirrhotic cardiomyopathy can mitigate heart failure risks.
Related Concept Videos
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:28Esophageal Varices-II: Clinical Features and Management
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
01:24Cirrhosis II: Pathophysiology
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:22Portal Hypertension
Portal hypertension is an increase in blood pressure within the portal venous system. Normally, this pressure is less than 5 mmHg. It is considered clinically significant when it rises above 10 mmHg. At this threshold, complications from altered blood flow and venous congestion emerge.EtiologyPortal hypertension arises from conditions that impede blood flow through the liver. The most common cause is cirrhosis, in which chronic liver injury leads to fibrotic scarring. This fibrosis narrows or...